Literature DB >> 9365761

HIV-1 detection in cervicovaginal secretions during pregnancy.

I Loussert-Ajaka1, L Mandelbrot, M C Delmas, H Bastian, J L Benifla, I Farfara, I de Vincenzi, S Matheron, F Simon, F Brun-Vezinet.   

Abstract

OBJECTIVE: To assess the reproducibility of and factors associated with HIV detection in cervicovaginal secretions (CVS).
DESIGN: Longitudinal study of 43 HIV-1-infected pregnant women in Paris.
METHODS: HIV DNA was detected in peripheral blood mononuclear cells (PBMC) by Amplicor and gag nested polymerase chain reaction (PCR) assays. The HIV genotype was determined by heteroduplex mobility assay. Amplicor and gag nested PCR assays were performed on serial CVS samples for HIV DNA detection, and the HIV Monitor test was used for HIV RNA detection in plasma and CVS.
RESULTS: A total of 144 CVS samples were collected from the women included in the study. HIV-1 DNA was detected in 36 (25%) of the 144 samples, from 16 (37.2%) of the 43 women. Results of HIV-1 DNA detection were concordant in the first two samples in 27 (84.4%) of the 32 women with at least two CVS samples. The last CVS sample collected in each woman was HIV-1 DNA-positive in 13 (30.2%) of the 43 women. Three factors were found to be independently associated with HIV-1 DNA detection in CVS: HIV-1 subtype B, absence of zidovudine therapy, and microbial cervicovaginal infection. HIV RNA was detected in CVS from 10 (23.3%) out of 43 women and correlated with DNA detection in the same sample and HIV RNA detection in plasma.
CONCLUSIONS: DNA and RNA PCR can be used to detect HIV in cells and supernatants of CVS. These techniques may be useful in cohort studies to investigate HIV transmission and to evaluate the efficacy of antiretroviral drugs to reduce HIV excretion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365761     DOI: 10.1097/00002030-199713000-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Validation of performance of the gen-probe human immunodeficiency virus type 1 viral load assay with genital swabs and breast milk samples.

Authors:  Dana DeVange Panteleeff; Sandra Emery; Barbra A Richardson; Christine Rousseau; Sarah Benki; Sharon Bodrug; Joan K Kreiss; Julie Overbaugh
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Prevalence and risk factors of cervicovaginal HIV shedding among HIV-1 and HIV-2 infected women in Dakar, Senegal.

Authors:  K Seck; N Samb; S Tempesta; C Mulanga-Kabeya; D Henzel; P S Sow; A Coll-Seck; S Mboup; I Ndoye; E Delaporte
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

3.  Detection and quantitation of human immunodeficiency virus type 1 in the female genital tract. The Division of AIDS Treatment Research Initiative 009 Study Group.

Authors:  P Baron; J Bremer; S S Wasserman; M Nowicki; B Driscoll; B Polsky; A Kovacs; P S Reichelderfer
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

Review 4.  The role of cell-associated virus in mother-to-child HIV transmission.

Authors:  Caitlin Milligan; Julie Overbaugh
Journal:  J Infect Dis       Date:  2014-12-15       Impact factor: 5.226

5.  Quantitation of human immunodeficiency virus type 1 RNA loads in cervicovaginal secretions in pregnant women and relationship between viral loads in the genital tract and blood.

Authors:  S García-Bujalance; G Ruiz; C Ladrón De Guevara; J M Peña; I Bates; J J Vázquez; A Gutiérrez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

6.  Efficient isolation of human immunodeficiency virus type 1 RNA from cervical swabs.

Authors:  A M Hajjar; P F Lewis; Y Endeshaw; J Ndinya-Achola; J K Kreiss; J Overbaugh
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

Review 7.  Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure.

Authors:  Omayma Amin; Jenna Powers; Katherine M Bricker; Ann Chahroudi
Journal:  Front Immunol       Date:  2021-10-21       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.